Valuation: Sanofi

Market Cap 90.46B 103B 83.52B 77.18B 146B 9,875B 149B 1,004B 390B 4,833B 387B 379B 16,776B P/E 2026 *
11.4x
P/E 2027 * 10.5x
Enterprise Value 100B 114B 92.47B 85.45B 162B 10,934B 165B 1,112B 432B 5,351B 429B 419B 18,575B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.91x
Free-Float
89%
Yield 2026 *
5.61%
Yield 2027 * 5.95%
1 week+1.08%
Current month+1.08%
1 month-3.59%
3 months-6.93%
6 months-9.18%
Current year-7.84%
1 week 36.4
Extreme 36.4
38.4
1 month 35.6
Extreme 35.6
39
3 years 35.6
Extreme 35.6
55
5 years 35.6
Extreme 35.6
55
10 years 30.6
Extreme 30.6
55
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 64 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.08%-6.47%-19.66% 104B
-0.97%+2.97%+57.80%+170.79% 1,102B
-0.57%+4.60%+70.53%+66.55% 643B
-0.46%+1.19%+33.87%+88.89% 450B
-1.35%+1.86%+29.96%+26.26% 336B
-0.71%+0.72%+28.85%+46.77% 288B
-1.31%-0.26%-28.18%-39.13% 222B
-0.08%+2.11%+24.23%+64.18% 199B
-0.92%+7.79%+22.26%+79.39% 169B
+0.27%+1.24%-5.64%-32.24% 137B
Average -0.70%+2.26%+22.72%+45.18% 393.9B
Weighted average by Cap. -0.81%+2.07%+39.34%+83.39%

Financials

2026 *2027 *
Net sales 47.19B 53.8B 43.56B 40.26B 76.3B 5,151B 77.83B 524B 203B 2,521B 202B 198B 8,751B 50.26B 57.3B 46.4B 42.88B 81.27B 5,486B 82.89B 558B 217B 2,685B 215B 210B 9,320B
Net income 7.99B 9.11B 7.38B 6.82B 12.92B 873B 13.18B 88.71B 34.47B 427B 34.22B 33.47B 1,482B 8.9B 10.15B 8.22B 7.59B 14.39B 972B 14.68B 98.79B 38.39B 476B 38.11B 37.28B 1,651B
Net Debt 9.7B 11.06B 8.95B 8.27B 15.68B 1,059B 16B 108B 41.82B 518B 41.52B 40.61B 1,799B 5.6B 6.38B 5.17B 4.78B 9.05B 611B 9.23B 62.12B 24.14B 299B 23.97B 23.44B 1,038B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
09/07/26 37.60 0.00%
07/07/26 €37.60 +1.08%
06/07/26 €37.20 -1.06%
03/07/26 €37.60 0.00%
02/07/26 €37.60 +3.30%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
75.78EUR
Average target price
96.31EUR
Spread / Average Target
+27.10%

Quarterly revenue - Rate of surprise